Exact Mass: 375.1464
Exact Mass Matches: 375.1464
Found 185 metabolites which its exact mass value is equals to given mass value 375.1464,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Haloperidol
A phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279) CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7649; ORIGINAL_PRECURSOR_SCAN_NO 7647 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7684; ORIGINAL_PRECURSOR_SCAN_NO 7682 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7681; ORIGINAL_PRECURSOR_SCAN_NO 7680 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7678; ORIGINAL_PRECURSOR_SCAN_NO 7677 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7604; ORIGINAL_PRECURSOR_SCAN_NO 7602 CONFIDENCE standard compound; INTERNAL_ID 588; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7639; ORIGINAL_PRECURSOR_SCAN_NO 7638 D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist C78272 - Agent Affecting Nervous System > C323 - Butyrophenone D005765 - Gastrointestinal Agents > D000932 - Antiemetics CONFIDENCE standard compound; EAWAG_UCHEM_ID 3566 CONFIDENCE standard compound; INTERNAL_ID 1122 Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
Simmondsin
Simmondsin is found in coffee and coffee products. Simmondsin is a constituent of Simmondsia chinensis (jojoba) Simmondsin is an extract of jojoba seeds (pronounced "ho-HO-bah") (Simmondsia chinensis), it was traditionally thought to be a toxic substance due to jojoba seed meal causing weight loss in animals, but recently it has been researched as a potential treatment for reducing appetite of obese individuals by helping to reduce craving for food. Several mechanisms of action are thought to be involved in the appetite suppressant effect
Linifanib
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
N-[4-(3-Amino-1h-indazol-4-yl)phenyl]-n1-(2-fluoro-5-methylphenyl) urea
Theodrenaline
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol
[(1aS)-1a,1bα,2,5aα,6,6aβ-Hexahydro-6α-[(E)-3-(4-hydroxy-3-methoxyphenyl)propenoyloxy]-1aβ-(hydroxymethyl)oxireno[4,5]cyclopenta[1,2-c]pyran-2α-yl]β-D-glucopyranoside
1,3-diethyl 2-{[(2-{[3-(trifluoromethyl)pyridin-2-yl]amino}ethyl)amino]methylidene}propanedioate
4-(4,6-dimethyl-9-oxo-4,9-dihydro-1H-imidazo[1,2-a]pyrrolo[3,2-d]pyrimidin-7-yl)-2-methoxycarbonylamino-butyric acid methyl ester
N-[2-(4-Hydroxyphenyl)ethyl]-3-(ethylthio)-3-(4-hydroxy-3-methoxyphenyl)propanamide
Linifanib
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
haloperidol
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AD - Butyrophenone derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist C78272 - Agent Affecting Nervous System > C323 - Butyrophenone D005765 - Gastrointestinal Agents > D000932 - Antiemetics Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.
Ala Asp Gly Asn
Ala Asp Asn Gly
Ala Gly Asp Asn
Ala Gly Asn Asp
Ala Asn Asp Gly
Ala Asn Gly Asp
Asp Ala Gly Asn
Asp Ala Asn Gly
Asp Gly Ala Asn
Asp Gly Gly Gln
Asp Gly Asn Ala
Asp Gly Gln Gly
Asp Asn Ala Gly
Asp Asn Gly Ala
Asp Gln Gly Gly
Glu Gly Gly Asn
Glu Gly Asn Gly
Glu Asn Gly Gly
Gly Ala Asp Asn
Gly Ala Asn Asp
Gly Asp Ala Asn
Gly Asp Gly Gln
Gly Asp Asn Ala
Gly Asp Gln Gly
Gly Glu Gly Asn
Gly Glu Asn Gly
Gly Gly Asp Gln
Gly Gly Glu Asn
Gly Gly Asn Glu
Gly Gly Gln Asp
Gly Asn Ala Asp
Gly Asn Asp Ala
Gly Asn Glu Gly
Gly Asn Gly Glu
Gly Gln Asp Gly
Gly Gln Gly Asp
Asn Ala Asp Gly
Asn Ala Gly Asp
Asn Asp Ala Gly
Asn Asp Gly Ala
Asn Glu Gly Gly
Asn Gly Ala Asp
Asn Gly Asp Ala
Asn Gly Glu Gly
Asn Gly Gly Glu
Gln Asp Gly Gly
Gln Gly Asp Gly
Gln Gly Gly Asp
Simmondsin
benzyl 4-[3-(aminomethyl)azetidin-1-yl]piperidine-1-carboxylate,dihydrochloride
tert-butyl 4-[2-nitro-4-(trifluoromethyl)phenyl]piperazine-1-carboxylate
D-PHENYLALANINE, BETA-PHENYL-N-[(PHENYLMETHOXY)CARBONYL]-
(2R)-2-(phenylmethoxycarbonylamino)-3-(4-phenylphenyl)propanoic acid
7-((S)-7-amino-5-azaspiro[2.4]heptan-5-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(TriMethyl)pentaMethylcyclopentadienylplatinuM(IV), 99\\%
Ethyl-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside
Methyl-5-hydroxy-1-methyl-6-oxo-2-[2-(phenylmethoxycarbonylamino) propan-2-yl]pyrimidin-4-carboxylate
5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol
4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-propylthieno[2,3-d]pyrimidine
(1-(5-Chloropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone
(1-(3-chloropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone
(6,7-Difluoro-quinazolin-4-YL)-(1-methyl-2,2-diphenyl-ethyl)-amine
Theodrenaline
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
(1R,2S,3S,4S,5S,8R,9R,12R)-5-hydroxy-4-methyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4,8-tricarboxylate
2-[[2-[(1-Cyclohexyl-5-tetrazolyl)thio]-1-oxoethyl]amino]benzoic acid methyl ester
(2Z)-2-[2-hydroxy-3,4-dimethoxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexylidene]acetonitrile
(1R,9S,10S,11S)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-N-[(3,5-difluorophenyl)methyl]-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
6-{(E)-2-[4-(butan-2-yloxy)-3-ethoxyphenyl]ethenyl}-5-nitropyrimidine-2,4-diol
Acetonitrile, ((2S,3R,4S,6R)-6-(beta-D-glucopyranosyloxy)-2-hydroxy-3,4-dimethoxycyclohexylidene)-, (2Z)-
FATP1-IN-1
FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively[1].
Lixumistat (acetate)
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model[1][2]. Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors[3].
NMDA-IN-1
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.
